Table 1

Demographic and clinical characteristics of PMR patients, total controls and RA patients*

PMR patients (n=136)Total control group (n=149)RA patients (n=94)p (1 vs 2)p (1 vs 3)
Age, years, mean±SD74±7.564±9.965.4±10<0.001<0.001
Age >65 years894753<0.001<0.001
Sex (M/F)29.6/70.428.6/71.427/73NSNS
Duration of symptoms, weeks, mean±SD12.9±1013.3±1112.4±10.5NSNS
ESR, mm/h, mean±SD60±2429±2438±26<0.001<0.001
ESR >40 mm/h7926.938.5<0.001<0.001
CRP, mg/dl, mean±SD5.09±4.261.73±2.442.27±2.61<0.001<0.001
CRP >0.5, mg/dL98.554.171.9<0.001<0.001
Positive RF (>40 UI/mL)2.225.641.7<0.001<0.001
Positive ACPA†
(>40 U/mL)
Morning stiffness, min, mean±SD164±10962±7485±81<0.001<0.001
Peripheral joint involvement38.2‡91.899<0.001<0.001
  • *Values are percentage unless specified.

  • †ACPA were determined in 69 PMR patients.

  • ‡88% had monoarthritis or oligoarthritis involving knee, ankle and/or wrist.

  • ACPA, anticitrullinated protein antibodies; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; PMR, polymyalgia rheumatica; RA, rheumatoid arthritis; RF, rheumatoid factor.